Stay updated on Psilocybin Safety & Efficacy for Body Dysmorphic Disorder Clinical Trial
Sign up to get notified when there's something new on the Psilocybin Safety & Efficacy for Body Dysmorphic Disorder Clinical Trial page.

Latest updates to the Psilocybin Safety & Efficacy for Body Dysmorphic Disorder Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe clinical-trial record for a Phase 2 study of psilocybin for body dysmorphic disorder is displayed, including its eligibility criteria, treatment plan, primary outcome measure, investigators, and study documents.SummaryDifference39%

- Check17 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.2 to v3.8.0; the study record still displays a 403 Forbidden error.SummaryDifference0.2%

- Check24 days agoChange DetectedA site-wide banner announces that NIH content may use “Super Intelligence” in place of “Artificial Intelligence” during a terminology transition.SummaryDifference1%

- Check31 days agoChange DetectedThe site's footer revision changed from v3.7.1 to v3.7.2. The study page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check38 days agoChange DetectedThe site footer revision label changed from v3.7.0 to v3.7.1; no study record content is shown.SummaryDifference0.2%

- Check58 days agoChange DetectedThe study page now displays a 403 Forbidden error, blocking access to the usual study details. This indicates an access issue rather than content changes.SummaryDifference16%

Stay in the know with updates to Psilocybin Safety & Efficacy for Body Dysmorphic Disorder Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Psilocybin Safety & Efficacy for Body Dysmorphic Disorder Clinical Trial page.